Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is …

angiotensin converting enzyme
chronic disease
renal impairment
semaglutide
Novo Nordisk Investigational Site
 (8.7 away) Contact site
  • 960 views
  • 26 Nov, 2020
  • +519 other locations
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety …

antiseptics
secukinumab
abscess
hidradenitis
Novartis Investigative Site
 (8.7 away) Contact site
  • 909 views
  • 08 Oct, 2020
  • +111 other locations
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.

epidermal growth factor receptor
anthracyclines
gilbert's syndrome
taxane
capecitabine
Universitaetsklinikum Erlangen
 (8.7 away) Contact site
  • 309 views
  • 21 Oct, 2020
  • +114 other locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first …

phototherapy
systemic therapy
apremilast
cc-10004
plaque psoriasis
Universitatsklinikum Erlangen
 (9.5 away) Contact site
  • 98 views
  • 27 Aug, 2020
  • +191 other locations
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G 3, moderate or severe). Approximately 332 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 …

apremilast
cc-10004
plaque psoriasis
Hautklinik Universitatsklinikum Erlangen
 (8.7 away) Contact site
  • 210 views
  • 28 Oct, 2020
  • +119 other locations
A Study of PRN1008 in Patients With Pemphigus

This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded Treatment Period) followed by an Open-Label Extension Period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period …

renal function
autoantibody titer
pemphigus foliaceus
Central Recruiting (Principia Biopharma)
 (8.7 away) Contact site
  • 158 views
  • 26 Aug, 2020
  • +158 other locations
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma. The primary study hypotheses are that: 1) The combination …

measurable disease
cytotoxic t-lymphocyte antigen 4
metastatic melanoma
solid tumour
advanced melanoma
Universitaetsklinikum Erlangen ( Site 0044)
 (8.7 away) Contact site
  • 150 views
  • 15 Nov, 2020
  • +105 other locations
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 300 patients will be enrolled.

cyst
diastolic blood pressure
systolic blood pressure
Universit tsklinikum Erlangen, Med4
 (8.7 away) Contact site
  • 270 views
  • 23 Nov, 2020
  • +108 other locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. …

pembrolizumab
major surgery
mk-3475
metastasis
Universit tsklinikum Erlangen ( Site 2408)
 (8.7 away) Contact site
  • 510 views
  • 26 Nov, 2020
  • +191 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

doxorubicin
epidermal growth factor receptor
paclitaxel
progesterone
epirubicin
Universitaetsklinikum Erlangen ( Site 1001)
 (8.7 away) Contact site
  • 188 views
  • 26 Nov, 2020
  • +271 other locations